Kamhada has signed distribution agreements for 3 products – the capital market

The dual bio-pharmaceutical company

Kamhada
+ 0.54%

Base:2,237

opening:2,221

Tall:2,291

low:2,205

change:4,231,145

Page Quote News Graphs Company Profile Recommendations


More articles on the subject:




Announces that it has signed two new agreements with two international pharmaceutical companies for the distribution of three biosimilar products in Israel, the revenue potential of which is estimated at $ 5-7 million per year. KamHada expects to begin marketing the products, with the approval of the Ministry of Health in Israel and the European Health Authority (EMA), between the years 2022-2024.

Kamhada, which specializes in plasma-based products, already distributes six Biosilmer products in Israel, developed by Albotech, which have potential sales of $ 20-30 million a year. “The distribution of the total portfolio of biosimilar products is expected to support the expected future growth in sales and profitability of our distribution sector,” said Amir London, CEO of KamaDa.

The company has a unique technology used to purify and separate proteins from human plasma for the production of high-purified liquid alpha-1 antitrypsin (AAT) and the production of other proteins (immunoglobulins) from plasma. KamHada has developed GLASSIA, the first FDA-approved liquid AAT product that it markets in the U.S. through a strategic partnership with Takeda and other countries through local distributors.

Another notable product in the company’s portfolio is KamRab, also FDA approved, based on human antibodies against rabies for preventive treatment after suspected infection from the disease. KamHada markets additional plasma products in about 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Alongside this the company has a number of developments that are in the clinical trials phase.